Vanguard Personalized Indexing Management LLC Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Vanguard Personalized Indexing Management LLC increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 17.5% in the second quarter, Holdings Channel.com reports. The firm owned 7,153 shares of the biopharmaceutical company’s stock after purchasing an additional 1,067 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Alnylam Pharmaceuticals were worth $1,738,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in ALNY. Capital International Investors grew its position in shares of Alnylam Pharmaceuticals by 15.8% in the fourth quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock valued at $686,641,000 after purchasing an additional 488,814 shares during the period. Vanguard Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after acquiring an additional 287,064 shares during the last quarter. Capital Research Global Investors boosted its holdings in Alnylam Pharmaceuticals by 7.3% in the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after acquiring an additional 214,908 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Alnylam Pharmaceuticals by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after acquiring an additional 201,784 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Alnylam Pharmaceuticals in the first quarter valued at $18,886,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Barclays lifted their target price on Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Raymond James lifted their target price on Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Citigroup boosted their price objective on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Bank of America boosted their price objective on Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Finally, JPMorgan Chase & Co. boosted their price objective on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research note on Monday, August 26th. Seven analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $279.14.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the business’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $276,726.02. Following the completion of the sale, the executive vice president now directly owns 14,181 shares of the company’s stock, valued at $3,275,669.19. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $276,726.02. Following the completion of the transaction, the executive vice president now directly owns 14,181 shares of the company’s stock, valued at $3,275,669.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 8,301 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $1,917,447.99. Following the transaction, the chief executive officer now directly owns 80,534 shares of the company’s stock, valued at $18,602,548.66. The disclosure for this sale can be found here. Insiders sold a total of 103,148 shares of company stock valued at $25,658,824 over the last three months. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Down 0.9 %

Shares of Alnylam Pharmaceuticals stock opened at $273.88 on Friday. The firm has a market cap of $34.64 billion, a P/E ratio of -102.19 and a beta of 0.38. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $287.55. The business has a 50-day moving average price of $260.11 and a 200 day moving average price of $199.07.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. The firm’s quarterly revenue was up 107.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.21) earnings per share. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.